BCL2 interacting protein 3 pseudogene 15Genealiases: []
Q-omics provides the consensus-scored BNIP3P15 profile across patient tissues and cancer cell-line models. BNIP3P15 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, BNIP3P15 is differentially expressed in 11, with the highest sampling consensus in LUSC. Additionally, BNIP3P15 RNA expression shows 14,237 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, LUSC, and THYM as cancer lineages where BNIP3P15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BNIP3P15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BNIP3P15 survival associations across molecular data types. BNIP3P15 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BNIP3P15 RNA expression–survival associations across cancer types. High BNIP3P15 expression shows unfavorable associations in LIHC, LGG, UCEC, LUSC and READ, but favorable associations in UVM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for BNIP3P15 RNA expression.
This table summarizes BNIP3P15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for BNIP3P15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BNIP3P15 shows lower tumor expression in LUSC, COAD, KICH and HNSC and higher tumor expression in KIRC and BLCA. The LUSC box plot shows higher BNIP3P15 RNA expression in normal versus tumor tissue (log2 FC = −0.455, t-test p < 0.001).
This table shows molecular features associated with BNIP3P15 in patient tissues and cancer cell lines. In patient samples, BNIP3P15 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
